Examkin

Patient Management

2074 questions

All types2,074Multiple choice1,048Multiple select393Matching221Ordering412
Question 21Question →

A 55-year-old man is brought to the emergency department by firefighters after being rescued from an enclosed structural house fire. The patient complains of a severe sore throat, painful swallowing, and shortness of breath. Vital signs are temperature 37.2°C (99.0°F), blood pressure 135/85 mm Hg, pulse 115/min, and respirations 24/min. Oxygen saturation is 96% on room air. Physical examination reveals singed facial hair, carbonaceous sputum in the oropharynx, and bilateral scattered wheezes. When the patient speaks, his voice is noticeably hoarse, and audible inspiratory stridor is present. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Perform immediate endotracheal intubation

Answer

The most appropriate next step in management is to perform immediate endotracheal intubation.
The correct response involves immediately securing a definitive airway. This patient presents with multiple classic signs of thermal upper airway injury resulting from smoke and heat inhalation, including singed facial hair, carbonaceous sputum, a hoarse voice, and inspiratory stridor. Thermal injury causes massive and rapid upper airway edema. When a patient develops stridor, it indicates that the airway is already significantly narrowed and complete obstruction is imminent. Because the swelling is progressive, early endotracheal intubation is required to secure the airway before it becomes completely occluded and impossible to intubate.

Step-by-Step Solution

1
Assess the patient's airway patency and respiratory status as the primary survey.
The patient demonstrates singed facial hair, carbonaceous sputum, hoarseness, and inspiratory stridor.
These findings are pathognomonic for upper airway thermal injury and severe mucosal edema.
2
Determine the immediate threat to life.
The presence of stridor and hoarseness indicates impending complete airway obstruction.
Thermal injury causes progressive edema that can rapidly completely occlude the airway, making later intubation impossible.
3
Select the most appropriate initial stabilization intervention.
Immediate endotracheal intubation is required.
A definitive airway must be established prior to diagnostic testing or secondary interventions.

Key Concept

Patients with thermal inhalation injury presenting with high-risk signs (hoarseness, stridor, singed facial hair, carbonaceous sputum) require early, prophylactic endotracheal intubation to prevent complete airway obstruction from progressive edema.
Question 22Question →

Evaluate the following distinct patient presentations following stabilization of their initial medical crises. Correlate each patient's current clinical trajectory and functional capacity with the most appropriate post-hospitalization discharge destination according to standardized transition criteria.

Click a left item, then click its matching right item

Items

61-year-old recovering from a complicated exploratory laparotomy. Currently hemodynamically stable but requires ongoing mechanical ventilation weaning via tracheostomy, continuous complex wound vacuum management, and total parenteral nutrition.
74-year-old post-ischemic stroke with left-sided hemiplegia and dysphagia. Medically stable, highly motivated, and actively participates in 3.5 hours of combined physical, occupational, and speech therapy daily without undue fatigue.
88-year-old treated for severe bilateral pneumonia. Infection has resolved, but the patient exhibits profound global deconditioning, is unable to stand independently, and reaches exhaustion after 40 minutes of physical exertion.
59-year-old with resolving methicillin-susceptible Staphylococcus aureus bacteremia. Afebrile for 72 hours, hemodynamically normal, and fully ambulatory. Requires 4 additional weeks of twice-daily intravenous cefazolin and lives with a supportive partner.

Matches

Show answer & explanation

Answer

The complicated laparotomy patient requiring vent weaning and TPN is matched to an extended acute care hospital. The stroke patient tolerating 3.5 hours of therapy is matched to an intensive multidisciplinary rehabilitation hospital. The deconditioned pneumonia patient tolerating limited exertion is matched to a subacute care facility. The stable bacteremia patient needing IV antibiotics is matched to a community-based dwelling with home infusion support.
Optimal care transitions require aligning a patient's medical and functional needs with facility capabilities. Extended acute care hospitals (LTACHs) are reserved for patients with severe medical complexities (vent weaning, multiple IV drips, extensive wounds) needing extended hospitalization. Intensive rehabilitation hospitals (IRFs) are appropriate for patients with significant functional deficits who are medically stable and can tolerate at least 3 hours of therapy daily. Subacute care facilities (SNFs) cater to patients needing skilled nursing or rehabilitation who cannot meet the 3-hour daily therapy threshold. Home infusion (OPAT) is ideal for stable, independent patients needing only IV medications.

Step-by-Step Solution

1
Analyze the functional status and medical complexity of the patient requiring tracheostomy weaning and TPN.
High medical complexity requiring physician oversight and respiratory therapy, but stable hemodynamics.
To differentiate between standard ward level of care and specialized prolonged acute care.
2
Evaluate the therapy tolerance of the stroke patient.
The patient tolerates over 3 hours of multidomain therapy daily.
The 3-hour threshold is the standard functional requirement for admission to an intensive rehabilitation facility.
3
Assess the rehabilitation needs and exertion limit of the post-pneumonia patient.
The patient needs rehabilitation but fatigues after 40 minutes, falling short of intensive rehab requirements.
Identifies the need for a lower-intensity skilled nursing or subacute environment to prevent therapy failure.
4
Determine the ongoing medical requirements for the bacteremia patient.
The patient only needs IV antibiotics with no skilled nursing needs beyond line management, and has good social support.
Confirms suitability for outpatient parenteral antimicrobial therapy (OPAT) at home.

Key Concept

Matching patient acuity, medical complexity, and functional therapy tolerance to specific post-acute care setting admission criteria.
Question 23Question →

A 28-year-old male is brought to the emergency department by paramedics after being struck by a motor vehicle at highway speeds. He is unresponsive upon arrival. Vital signs are temperature 35.8°C (96.4°F), heart rate 142/min, blood pressure 68/40 mm Hg, and respiratory rate 36/min. Oxygen saturation is 82% on a high-flow non-rebreather mask. Physical examination reveals a Glasgow Coma Scale score of 6 (E1, V1, M4). The right hemithorax is hyperresonant to percussion with absent breath sounds. The trachea is palpably deviated to the left. The patient has pale, cool, and diaphoretic extremities with thready peripheral pulses. Which of the following are the most appropriate immediate next steps in the management of this patient? (Select 2 options)

Select all that apply

Show answer & explanation

Answer: Perform right-sided needle or finger thoracostomy; Perform endotracheal intubation with in-line cervical spine stabilization

Answer

The most appropriate immediate next steps are performing a right-sided needle or finger thoracostomy and performing endotracheal intubation with in-line cervical spine stabilization.
This patient presents with a Glasgow Coma Scale score of 6 and signs of a right-sided tension pneumothorax (absent breath sounds, hyperresonance, tracheal deviation, and profound shock). According to Advanced Trauma Life Support (ATLS) protocols, primary survey abnormalities must be addressed immediately as they are identified. A GCS of 8 or less requires definitive airway protection via endotracheal intubation with in-line cervical spine stabilization. Simultaneously, the tension pneumothorax must be immediately decompressed using a needle or finger thoracostomy to restore venous return and cardiac output. These life-saving stabilization steps must occur concurrently and prior to any diagnostic imaging.

Step-by-Step Solution

1
Evaluate the primary survey (ABCs) and vital signs.
The patient has impending airway failure (GCS 6), severe respiratory distress/hypoxia, and profound shock (BP 68/40 mm Hg).
Trauma resuscitation requires immediate identification of life-threatening injuries before definitive diagnostics.
2
Diagnose the cause of the respiratory and hemodynamic compromise based on physical exam.
Absent right-sided breath sounds, hyperresonance, and leftward tracheal deviation indicate a right-sided tension pneumothorax.
Tension pneumothorax restricts venous return, causing obstructive shock, and must be recognized clinically.
3
Select the immediate simultaneous interventions for the identified life threats.
The patient requires immediate airway protection (intubation) and chest decompression (thoracostomy).
Simultaneous execution of airway management and treatment of tension pneumothorax is the standard of care in ATLS guidelines.

Key Concept

In a hemodynamically unstable trauma patient, immediate clinical diagnosis and treatment of life-threatening conditions (e.g., tension pneumothorax) and airway protection (for GCS ≤ 8) take precedence over diagnostic imaging and must be performed simultaneously.
Question 24Question →

A 38-year-old construction worker is evaluated in the trauma center immediately after falling approximately 25 feet from a scaffolding. Prehospital personnel report progressive unresponsiveness during transit. On presentation, the patient's temperature is 36.4 °C (97.5 °F), blood pressure is 78/42 mm Hg, heart rate is 134/min, and respiratory rate is 10/min. Oxygen saturation is 88% on a non-rebreather mask. A rigid cervical collar is in place. The Glasgow Coma Scale score is 6 (eyes 1, verbal 2, motor 3). The patient has shallow, gurgling respirations with visible pooling of blood and secretions in the oropharynx. Physical examination reveals a pelvis that is unstable to lateral compression and a large ecchymosis over the left flank.

Which of the following is the most appropriate initial step in the management of this patient?

Show answer & explanation

Answer: Secure the airway via endotracheal intubation

Answer

Secure the airway via endotracheal intubation
In the management of polytrauma patients, the Advanced Trauma Life Support (ATLS) primary survey dictates prioritizing interventions in the ABCDE sequence (Airway, Breathing, Circulation, Disability, Exposure). This patient's Glasgow Coma Scale (GCS) score of 6, combined with shallow respirations and pooling of oropharyngeal secretions, indicates an inability to protect the airway and impending respiratory failure. Therefore, immediate endotracheal intubation (while maintaining strict cervical spine precautions) is the highest priority and most urgent life-saving step. This must take physiological precedence over hemodynamic resuscitation and all diagnostic evaluations.

Step-by-Step Solution

1
Assess the primary survey priorities
Patient has an unsecured airway (GCS 6, pooling secretions, gurgling)
Airway compromise is the most rapid cause of death in trauma patients.
2
Evaluate competing life threats
Hemorrhagic shock from pelvic/abdominal trauma is present but bleeding is internal
In the absence of exsanguinating external hemorrhage, airway takes absolute precedence over circulation.
3
Determine the immediate next step
Endotracheal intubation
Establishes a definitive airway before proceeding to breathing and circulation management.

Key Concept

In polytrauma, the primary survey mandates securing the airway (A) before addressing circulation (C), except in cases of massive, compressible external hemorrhage.
Question 25Question →

A 54-year-old man is diagnosed with moderate-to-severe rheumatoid arthritis following an extensive evaluation for symmetric small joint pain and prolonged morning stiffness. His rheumatologist initiates disease-modifying treatment with weekly oral methotrexate and daily folic acid supplementation. The patient has a past medical history of essential hypertension, which is well-controlled with amlodipine. He is a non-smoker and does not consume alcohol. Baseline laboratory studies, including a comprehensive metabolic panel, complete blood count, hepatitis serologies, and a chest radiograph, were all within normal limits prior to starting the new medication.

Which of the following parameters are required for routine, ongoing monitoring of this patient's new pharmacotherapy? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Complete blood count; Hepatic transaminases

Answer

The correct parameters for routine monitoring of methotrexate therapy are a complete blood count and hepatic transaminases.
Methotrexate is a folate antimetabolite that competitively inhibits dihydrofolate reductase. Because it targets rapidly dividing cells, it frequently causes dose-dependent myelosuppression (leukopenia, thrombocytopenia, macrocytic anemia) and hepatotoxicity. Consequently, the standard of care requires routine periodic monitoring of a complete blood count and hepatic transaminases. Renal function (serum creatinine) must also be routinely monitored because the drug is primarily cleared by the kidneys, and declining renal function significantly increases the risk of systemic toxicity.

Step-by-Step Solution

1
Identify the prescribed high-risk medication and its common organ toxicities.
The patient was started on methotrexate, an antimetabolite known to cause bone marrow suppression, hepatotoxicity, and mucosal irritation.
Recognizing the side effect profile is necessary to determine what organ systems require active surveillance.
2
Determine the standard guideline-concordant tests required for ongoing surveillance.
Standard clinical guidelines mandate regular monitoring of a complete blood count, hepatic transaminases, and serum creatinine.
These tests detect subclinical myelosuppression and liver injury before irreversible damage occurs.
3
Rule out tests that belong to different medications or diseases.
Ophthalmologic exams are for hydroxychloroquine, uric acid is for gout, and pulmonary function tests are only indicated if symptoms of pneumonitis develop.
Avoids the application of unnecessary or incorrect monitoring protocols.

Key Concept

Patients on methotrexate therapy require ongoing, routine laboratory monitoring of their complete blood count, hepatic transaminases, and serum creatinine to safely detect drug-induced myelosuppression and hepatotoxicity.
Question 26Question →

A 26-year-old pregnant woman, gravida 1 para 0, presents to her obstetrician at 16 weeks gestation for evaluation of a new rash. Over the past week, she has noted the appearance of non-pruritic, pink macules and papules spreading across her trunk and involving her palms and soles. She also reports mild fatigue and subjective low-grade fevers. Her first prenatal visit was two weeks ago, but she missed her scheduled laboratory testing. Her medical history is notable only for a severe anaphylactic reaction to amoxicillin during childhood, which resulted in wheezing and hospital admission. She takes a daily prenatal vitamin. Vital signs are within normal limits. Fetal heart tones are 145/min. Rapid plasma reagin testing is reactive at a titer of 1:32. A confirmatory Treponema pallidum particle agglutination test is also positive. Which of the following is the most appropriate next step in pharmacologic management?

Show answer & explanation

Answer: Inpatient penicillin desensitization followed by intramuscular benzathine penicillin G

Answer

Inpatient penicillin desensitization followed by intramuscular benzathine penicillin G
The correct intervention is inpatient penicillin desensitization followed by intramuscular benzathine penicillin G. This patient is presenting with secondary syphilis (characterized by a rash involving the palms and soles, a positive RPR, and a positive TP-PA) during her pregnancy. Penicillin is the only antibiotic with proven, reliable efficacy for treating maternal infection and crossing the placenta to prevent congenital syphilis in the fetus. Because she has a history of a severe, IgE-mediated allergic reaction to penicillin (anaphylaxis to amoxicillin), she cannot be given alternative regimens safely or effectively; the strict standard of care dictates admission for desensitization followed by definitive treatment with benzathine penicillin G.

Step-by-Step Solution

1
Interpret the clinical and laboratory findings.
The patient has secondary syphilis, evidenced by the characteristic palmar and plantar rash, a positive RPR, and a positive TP-PA.
Accurate diagnosis is required before selecting targeted antimicrobial therapy.
2
Identify the patient's specific physiological state and medication constraints.
The patient is pregnant and has a severe, IgE-mediated (anaphylactic) allergy to penicillins.
Pregnancy restricts the use of teratogenic medications, and the severe allergy history complicates first-line drug selection.
3
Select the guideline-concordant pharmacologic intervention.
Determine that penicillin is mandatory for maternal-fetal syphilis treatment, necessitating a formal desensitization protocol.
Alternative agents lack established efficacy for preventing congenital syphilis or are strictly contraindicated in this population.

Key Concept

Pregnant patients with syphilis and a penicillin allergy must undergo penicillin desensitization and treatment with penicillin, as it is the only regimen proven to effectively treat the mother and prevent congenital syphilis.
Estimated Time:1m 15s
Question 27Question →

A 54-year-old woman comes to the clinic for a routine health maintenance visit. She has no current symptoms and feels well. Her surgical history is significant for a total abdominal hysterectomy (removal of the uterus and cervix) with bilateral salpingo-oophorectomy performed 4 years ago for symptomatic, heavy uterine bleeding caused by leiomyomas. Surgical pathology at that time confirmed benign leiomyomas. A detailed review of her past gynecologic history reveals that she had an abnormal Papanicolaou (Pap) test 12 years ago, which led to a diagnosis of cervical intraepithelial neoplasia (CIN) grade 3. She was treated with a loop electrosurgical excision procedure (LEEP) with clear margins. Subsequent Pap tests prior to her hysterectomy were normal. She has not had any screening tests since her hysterectomy. Vital signs are within normal limits, and physical examination of the vaginal vault is unremarkable. Which of the following is the most appropriate next step in the preventive care of this patient?

Show answer & explanation

Answer: Perform vaginal cuff cytology and human papillomavirus (HPV) cotesting.

Answer

The correct answer is to perform vaginal cuff cytology and human papillomavirus (HPV) cotesting.
The correct action is to perform vaginal cuff cytology and human papillomavirus (HPV) cotesting. According to the US Preventive Services Task Force (USPSTF) and the American College of Obstetricians and Gynecologists (ACOG), women who have undergone a total hysterectomy (removal of the uterus and cervix) for benign indications should stop routine cervical cancer screening. However, a major exception exists: women with a history of high-grade precancerous cervical lesions (such as CIN 2 or CIN 3) or cervical cancer must continue routine screening for a total of 20 years after the initial treatment of the high-grade lesion, regardless of the hysterectomy and even if it extends screening past the age of 65. Because this patient was treated for CIN 3 12 years ago, she is still within the 20-year surveillance window and requires ongoing screening of the vaginal cuff.

Step-by-Step Solution

1
Evaluate the impact of the patient's surgical history on screening requirements.
The patient had a total hysterectomy (cervix removed) for benign leiomyomas. Normally, this permits the cessation of cervical cancer screening.
Routine cervical cancer screening is not recommended for individuals without a cervix unless they have specific high-risk historical factors.
2
Assess the patient's past gynecologic history for exceptions to the standard hysterectomy rule.
The patient has a documented history of cervical intraepithelial neoplasia (CIN) grade 3 treated 12 years ago.
A history of high-grade dysplasia (CIN 2 or 3) or cervical cancer is a critical exception that modifies standard screening cessation protocols.
3
Apply the appropriate guideline for a patient with a history of CIN 3 who subsequently underwent a hysterectomy.
The patient must undergo vaginal cuff screening (via cytology or cotesting) for a total of 20 years post-treatment.
Current guidelines mandate 20 years of continuous surveillance after treatment for CIN 2/3. Because her treatment was 12 years ago, she requires 8 more years of screening, making testing indicated at this visit.

Key Concept

Women with a history of CIN 2, CIN 3, or cervical cancer must continue age-based screening for a total of 20 years after treatment, which involves vaginal cuff screening if a total hysterectomy is performed.
Estimated Time:1m 30s
Question 28Question →

An emergency medical services team brings a 58-year-old man to the resuscitation bay due to progressive, profound weakness and an inability to stand. The patient's husband reports that the patient missed his last two hemodialysis appointments because of a local transportation strike. The patient has a known history of end-stage renal disease secondary to hypertensive nephrosclerosis, as well as type 2 diabetes mellitus. Upon arrival, he is lethargic but arousable. Vital signs include a blood pressure of 105/65 mmHg, a heart rate of 42/min, and a respiratory rate of 16/min. An immediate 12-lead electrocardiogram demonstrates marked sinus bradycardia with absent P waves, peaked T waves, and a widened QRS complex. A point-of-care basic metabolic panel reveals a serum potassium concentration of 7.8 mEq/L7.8 \text{ mEq/L}. The clinical team consults nephrology for emergent hemodialysis but determines that temporizing pharmacologic stabilization is required immediately. Arrange the following pharmacologic interventions in the most appropriate sequential order for this patient's acute management.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: Intravenous calcium gluconate, followed by Intravenous regular insulin and 50% dextrose, followed by Oral sodium zirconium cyclosilicate.
The management of severe hyperkalemia with electrocardiographic changes requires a strict, prioritized approach: stabilize the myocardium, shift potassium intracellularly, and eliminate potassium from the body. Intravenous calcium gluconate is the absolute first priority as it rapidly antagonizes the membrane effects of hyperkalemia, preventing fatal arrhythmias within minutes. Once the myocardium is stabilized, intracellular shifting agents like intravenous regular insulin (co-administered with dextrose to prevent hypoglycemia) are used to temporarily lower serum potassium over 15 to 30 minutes. Finally, agents that physically remove potassium from the body, such as oral sodium zirconium cyclosilicate, are administered; these are given last in the acute sequence because they take hours to exert their effect while definitive therapy (hemodialysis) is arranged.

Step-by-Step Solution

1
Identify the life-threatening emergency.
The patient has severe hyperkalemia (7.8 mEq/L7.8 \text{ mEq/L}) with active cardiac toxicity evidenced by bradycardia, absent P waves, peaked T waves, and a widened QRS complex.
Recognizing electrocardiographic changes in the setting of extreme hyperkalemia dictates an immediate, protocol-driven pharmacologic sequence prior to definitive dialysis.
2
Prioritize myocardial stabilization.
Intravenous calcium gluconate is administered as the absolute first step.
Without immediate membrane stabilization, the patient is at imminent risk of deteriorating into ventricular fibrillation or asystole. Calcium acts within minutes.
3
Initiate intracellular potassium shifting.
Intravenous regular insulin (with dextrose to prevent hypoglycemia) is administered next.
Once the myocardium is protected, shifting potassium into cells temporarily lowers the dangerous extracellular concentration. This bridge therapy takes 15 to 30 minutes to work.
4
Initiate total body potassium elimination.
Oral sodium zirconium cyclosilicate is administered last among these choices.
While definitive removal requires hemodialysis for this anuric patient, gastrointestinal binders contribute to potassium elimination but have a delayed onset of several hours.

Key Concept

Stepwise pharmacologic management of severe hyperkalemia with electrocardiographic changes: 1) Stabilize myocardium, 2) Shift potassium intracellularly, 3) Eliminate potassium.
Estimated Time:1m 30s
Question 29Question →

Two weeks after initiating antihypertensive therapy, a 65-year-old man presents to the ambulatory care clinic for reassessment. His medical history is significant for type 2 diabetes mellitus complicated by microalbuminuria. At his previous visit, his blood pressure was 158/94158/94 mm Hg, and lisinopril was prescribed. Currently, the patient is asymptomatic, specifically denying dizziness, headaches, or peripheral swelling. Vital signs today show a blood pressure of 132/82132/82 mm Hg and a pulse of 7272/min. Physical examination is unremarkable.

A basic metabolic panel is obtained today, and the results are compared to his baseline labs from two weeks ago:

ParameterBaseline (2 weeks ago)Current (Today)
Serum sodium140 mEq/L139 mEq/L
Serum potassium4.3 mEq/L4.8 mEq/L
Blood urea nitrogen18 mg/dL22 mg/dL
Serum creatinine1.5 mg/dL1.8 mg/dL

Based on these findings, which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Continue lisinopril and schedule a routine follow-up

Answer

Continue lisinopril and schedule a routine follow-up
The patient's serum creatinine increased from 1.51.5 mg/dL to 1.81.8 mg/dL after starting lisinopril, representing a 2020% rise from baseline. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) decrease intraglomerular pressure by causing preferential vasodilation of the efferent arteriole. This hemodynamic change is beneficial for long-term renoprotection, particularly in patients with diabetic nephropathy, but it predictably reduces the glomerular filtration rate (GFR) slightly and increases serum creatinine. Current guidelines assert that a rise in serum creatinine of up to 3030% from baseline within the first few weeks of initiating an ACE inhibitor is acceptable. Because this patient's increase (2020%) is within the acceptable limit and his potassium level remains within normal limits (4.84.8 mEq/L), the most appropriate action is to continue the medication and proceed with routine outpatient monitoring.

Step-by-Step Solution

1
Calculate the percentage increase in serum creatinine from baseline.
1.8−1.5=0.31.8 - 1.5 = 0.3 mg/dL increase, which represents a 2020% rise.
To determine if the decline in renal function falls within the expected, safe physiological limits.
2
Evaluate the serum potassium level.
Potassium increased from 4.34.3 to 4.84.8 mEq/L, remaining within the normal range.
ACE inhibitors block aldosterone production, which can cause hyperkalemia. Levels must be monitored to ensure safety.
3
Determine the clinical significance of the laboratory changes.
The 2020% creatinine increase is below the 3030% threshold for concern, and the patient is asymptomatic with improved blood pressure.
An increase in creatinine of up to 3030% is expected due to efferent arteriolar vasodilation and is associated with long-term renoprotection.

Key Concept

An isolated increase in serum creatinine of up to 30% from baseline is an expected, benign physiological response to ACE inhibitor initiation and does not require medication discontinuation if hyperkalemia is absent.
Question 30Question →

A 65-year-old man presents to a primary care clinic with a 4-day history of worsening cough productive of yellow sputum, subjective fevers, and fatigue. He has a past medical history of hypertension, type 2 diabetes mellitus, and hyperlipidemia. His daily medications include lisinopril, metformin, simvastatin, and low-dose aspirin. Vital signs show a temperature of 38.2°C (100.8°F), blood pressure of 134/82 mmHg, heart rate of 92/min, and respiratory rate of 18/min. Pulse oximetry is 96% on room air. Physical examination reveals crackles in the right lower lung base. A chest radiograph demonstrates a right lower lobe infiltrate. The physician diagnoses community-acquired pneumonia. Given the patient's comorbidities, he is prescribed an outpatient oral regimen of amoxicillin-clavulanate and clarithromycin. Which of the following is the most appropriate modification to this patient's chronic medication regimen during his antibiotic therapy?

Show answer & explanation

Answer: Temporarily withhold simvastatin for the duration of the antibiotic course

Answer

Temporarily withhold simvastatin for the duration of the antibiotic course.
The correct action is to temporarily withhold simvastatin for the duration of the antibiotic course. Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, which is responsible for the hepatic metabolism of simvastatin. Coadministration of these two drugs significantly elevates simvastatin serum concentrations, markedly increasing the risk of severe statin-induced myopathy and life-threatening rhabdomyolysis. Because of this well-established and predictable interaction, the concurrent use of simvastatin (or lovastatin) and clarithromycin is absolutely contraindicated by the FDA. The safest and most practical management strategy for a patient requiring a short course of a strong CYP3A4 inhibitor is to simply pause the statin therapy until the antibiotic course is completed, as a brief interruption in lipid-lowering therapy poses no acute cardiovascular risk.

Step-by-Step Solution

1
Analyze the prescribed antibiotic regimen for potential drug-drug interactions.
Clarithromycin is identified as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.
Macrolides (excluding azithromycin) are notorious for causing significant pharmacokinetic interactions by inhibiting hepatic enzymes.
2
Evaluate the patient's chronic medications to identify CYP3A4 substrates.
Simvastatin is identified as a major substrate of CYP3A4.
Inhibition of CYP3A4 drastically decreases the clearance of simvastatin, leading to toxic serum concentrations.
3
Determine the appropriate clinical intervention to mitigate the identified interaction.
The concurrent use of clarithromycin and simvastatin is absolutely contraindicated; the statin must be withheld.
To prevent severe adverse effects such as myopathy and rhabdomyolysis, the offending medication (simvastatin) should be paused during the short course of the antibiotic.

Key Concept

Management of pharmacokinetic interactions between strong CYP3A4 inhibitors (clarithromycin) and CYP3A4 substrates (simvastatin).
Estimated Time:1m 0s
Question 31Question →

A 68-year-old man with symptomatic, recurrent atrial fibrillation has failed rate control strategies and is planned for rhythm control with amiodarone. He has a history of coronary artery disease and heart failure with a left ventricular ejection fraction of 35%. You are planning his medication initiation and long-term follow-up. Arrange the following steps regarding the monitoring and treatment evaluation of this patient's amiodarone therapy in the correct chronological order, from baseline preparation to long-term surveillance.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: 1) Baseline organ function testing, 2) Acute ECG monitoring during loading, 3) 6-month thyroid and liver function surveillance, and 4) Annual pulmonary and ophthalmic screening.
Amiodarone is a highly effective antiarrhythmic, but it carries a massive burden of potential systemic toxicities due to its lipophilicity, high iodine content, and extremely long half-life. Safe management requires a strict temporal protocol: establishing baseline pulmonary, hepatic, and thyroid function; securing the acute loading phase against proarrhythmias; conducting 6-month interval checks for thyroid and hepatic dysfunction; and maintaining annual checks for chronic pulmonary or ocular damage.

Step-by-Step Solution

1
Establish baseline clinical parameters prior to drug exposure.
Liver function tests, thyroid function tests, chest radiograph, and pulmonary function tests (including DLCO) are obtained.
Amiodarone causes multi-organ toxicity. Baseline values are essential to differentiate drug-induced injury from pre-existing disease progression.
2
Observe for acute electrical complications during the initial drug loading.
The patient is placed on continuous inpatient telemetry.
The loading phase carries the highest acute risk for severe bradycardia, AV block, and QT prolongation leading to Torsades de Pointes.
3
Implement mid-term surveillance for endocrine and hepatic side effects.
TSH and transaminases are drawn at 6 months.
Due to its high iodine content and lipophilicity, amiodarone can induce thyrotoxicosis, hypothyroidism, and hepatotoxicity, typically becoming apparent within the first 6 to 12 months.
4
Maintain long-term screening for chronic structural toxicities.
Annual chest radiograph and slit-lamp eye exam are scheduled.
Amiodarone pulmonary toxicity (APT) and ocular complications (corneal microdeposits, optic neuropathy) can present insidiously after years of therapy.

Key Concept

Standardized monitoring protocol for amiodarone toxicity
Question 32Question →

An 82-year-old man with end-stage congestive heart failure (left ventricular ejection fraction of 15%) and severe chronic kidney disease (estimated glomerular filtration rate of 18 mL/min/1.73 m²) is admitted to the hospital with worsening dyspnea and generalized anasarca. This is his fourth admission in the past two months. He is functionally dependent and spends most of his day resting in a chair. Despite aggressive intravenous diuresis over the past 48 hours, he remains highly symptomatic with dyspnea at rest.

During morning rounds, the patient tells the attending physician, "I am so tired of fighting this. I don't want any more blood draws, machines, or hospitals. I just want to go home and be kept comfortable for whatever time I have left."

The physician evaluates the patient and determines that he is fully alert, oriented to person, place, and time, and demonstrates a clear understanding of his diagnosis, prognosis, and the fatal consequences of stopping aggressive medical therapy.

Later that afternoon, the patient's daughter, who is his legally designated healthcare proxy, arrives at the hospital. She is extremely distraught and insists, "You must do everything possible! Put him on dialysis and a breathing machine if you have to. I am his healthcare proxy, and I say he stays here for treatment."

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Initiate a referral for home hospice care and prescribe low-dose oral morphine to manage his dyspnea.

Answer

Initiate a referral for home hospice care and prescribe low-dose oral morphine to manage his dyspnea.
The correct response correctly synthesizes ethical principles and palliative symptom management. Because the patient demonstrates clinical capacity (understanding his diagnosis, prognosis, and the consequences of his choices), his autonomous decision to pursue comfort care supersedes the demands of his daughter. Her status as a healthcare proxy is only activated if he loses capacity. Transitioning him to home hospice honors his wishes. Furthermore, prescribing low-dose oral morphine is the medically appropriate treatment for dyspnea (air hunger) in end-stage heart failure, as it decreases the central respiratory drive and reduces the sensation of breathlessness safely and rapidly.

Step-by-Step Solution

1
Assess the patient's decision-making capacity regarding his goals of care.
The physician determined the patient is alert, oriented, and understands his prognosis and the consequences of his choice. Therefore, he has full clinical decision-making capacity.
Capacity is the foundation of medical ethics; a capable patient's choices dictate the plan of care.
2
Evaluate the authority of the healthcare proxy in this specific scenario.
The daughter's demands are overridden by the patient's autonomous request.
A healthcare proxy (surrogate) only has decision-making authority when the primary patient lacks clinical capacity. Since he has capacity, her legal status as proxy is currently inactive.
3
Determine the appropriate clinical disposition based on the patient's goals.
A referral for home hospice is indicated.
The patient explicitly requested to stop machines/hospitals and focus on comfort at home, which perfectly aligns with hospice care.
4
Select the appropriate pharmacologic management for his acute dyspnea (air hunger).
Prescribe low-dose, short-acting oral morphine.
Short-acting opioids (like oral morphine) are the standard of care for relieving dyspnea in end-stage cardiopulmonary disease. Long-acting or delayed-onset opioids (like fentanyl patches) are contraindicated for acute symptoms in opioid-naive patients.

Key Concept

In patients with clinical capacity, their autonomous healthcare decisions supersede those of a designated healthcare proxy; home hospice with short-acting opioids is the standard of care for capable patients choosing comfort over life-prolonging measures.
Estimated Time:1m 30s
Question 33Question →

During a routine health maintenance visit, a 32-year-old female requests advice on her long-term cancer screening needs. She feels entirely well and has no acute concerns. Her past medical history is notable for classic Hodgkin lymphoma, which was diagnosed when she was a 21-year-old college student. At that time, her treatment consisted of 6 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) alongside involved-field radiation therapy to her neck and mediastinum. She achieved complete remission and has had no disease recurrence in the 11 years since.

Her family history is unremarkable for malignancies. She does not use tobacco, consumes alcohol in moderation, and exercises regularly. Vital signs are within normal limits. A thorough physical examination, including clinical breast and thyroid palpation, reveals no masses or adenopathy. Review of her records indicates a normal Pap smear and negative high-risk human papillomavirus testing performed 2 years ago.

Which of the following is the most appropriate next step in preventive care for this patient?

Show answer & explanation

Answer: Annual screening mammography and breast magnetic resonance imaging

Answer

The most appropriate step is annual screening mammography and breast magnetic resonance imaging.
The correct answer is annual screening mammography and breast magnetic resonance imaging (MRI). Patients who received ≥10\ge 10 Gy of thoracic radiation between the ages of 1010 and 3030 years (e.g., as part of mantle field radiation for Hodgkin lymphoma) have a significantly elevated lifetime risk of developing secondary breast cancer. This risk approaches that seen in patients with BRCA genetic mutations. Consequently, major oncology and radiology guidelines recommend high-risk screening for this population. This regimen consists of annual screening mammography and annual breast MRI beginning 88 years after the completion of radiation therapy, but not before age 2525. Since this patient was treated 1111 years ago at age 2121, she meets all criteria and should begin this intensive screening regimen immediately.

Step-by-Step Solution

1
Identify the patient's major risk factor for secondary malignancies.
The patient received involved-field radiation therapy to the neck and mediastinum at age 21.
Prior medical treatments, especially radiation and certain chemotherapies during adolescence or young adulthood, significantly alter future cancer screening requirements.
2
Determine the appropriate breast cancer screening protocol based on this risk factor.
Guidelines recommend annual mammography and breast MRI starting 8 years after radiation or at age 25 (whichever is later) for women who received thoracic radiation between ages 10 and 30.
Thoracic radiation in this age window drastically increases the lifetime risk of breast cancer due to the direct exposure of developing breast tissue.
3
Evaluate the patient's current age and time since treatment to select the immediate next step.
The patient is 32 years old and it has been 11 years since her radiation therapy. Therefore, she is immediately due for annual mammography and breast MRI.
She meets both the age (≥25\ge 25 years) and time interval (≥8\ge 8 years) criteria to begin high-risk screening.

Key Concept

High-risk breast cancer screening after thoracic radiation
Estimated Time:1m 15s
Question 34Question →

A 72-year-old woman is evaluated in the ambulatory care clinic for a routine follow-up. She has a history of type 2 diabetes mellitus, osteoarthritis, hypertension, and recurrent uncomplicated urinary tract infections. Her current medications include metformin 1000 mg twice daily, sitagliptin 100 mg daily, meloxicam 15 mg daily, nitrofurantoin 100 mg daily, and amlodipine 10 mg daily. The patient reports feeling well overall, though she mentions mild fatigue over the past few weeks. Blood pressure is 132/82 mmHg, and pulse is 76/min. Physical examination is unremarkable, with no peripheral edema.

Laboratory results from today are compared to those from six months ago:

Laboratory TestCurrentSix Months Ago
Blood urea nitrogen42 mg/dL18 mg/dL
Serum creatinine2.6 mg/dL1.1 mg/dL
eGFR19 mL/min/1.73 m²55 mL/min/1.73 m²
Serum potassium4.8 mEq/L4.2 mEq/L

Based on the patient's current laboratory results, which of the following medications must be entirely DISCONTINUED? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Metformin; Meloxicam; Nitrofurantoin

Answer

Metformin, Meloxicam, and Nitrofurantoin must be discontinued.
This patient has developed severe renal impairment (eGFR < 30 mL/min/1.73 m²). In this setting, metformin must be discontinued due to a significantly elevated risk of life-threatening lactic acidosis. Meloxicam, an NSAID, must be stopped because it inhibits prostaglandins that are actively dilating the afferent arteriole to maintain glomerular filtration, further worsening renal function. Nitrofurantoin must also be discontinued because it is essentially cleared by glomerular filtration; at an eGFR < 30 mL/min/1.73 m², it fails to reach therapeutic levels in the urinary tract to prevent UTIs and instead accumulates systemically, leading to pulmonary toxicity and peripheral neuropathy.

Step-by-Step Solution

1
Analyze the patient's updated laboratory findings.
The patient's eGFR has rapidly declined from 55 to 19 mL/min/1.73 m², indicating new-onset Stage 4 chronic kidney disease (CKD) or acute-on-chronic kidney injury.
Renal function directly determines the safety, efficacy, and necessary dosing adjustments for many pharmacologic agents.
2
Evaluate the current medication list against the new eGFR of 19 mL/min/1.73 m².
Identify which medications are absolutely contraindicated, which need dose adjustments, and which are safe to continue.
Continuing contraindicated medications in advanced CKD can lead to severe systemic toxicity or worsen renal failure.
3
Select the medications that require complete discontinuation.
Metformin (lactic acidosis risk), meloxicam (worsens renal perfusion), and nitrofurantoin (lack of efficacy and high toxicity risk) must be stopped. Sitagliptin only requires a dose reduction, and amlodipine requires no changes.
Differentiating between drugs requiring dose adjustments and those requiring absolute discontinuation is critical for safe medication reconciliation.

Key Concept

Medication reconciliation and identification of absolute pharmacologic contraindications in the setting of severely impaired renal function (eGFR < 30 mL/min/1.73 m²).
Question 35Question →

A 34-year-old woman with Hashimoto thyroiditis comes to the clinic for a routine follow-up evaluation. She has been stable on a daily levothyroxine dose of 112 mcg112 \text{ mcg} for the past 2 years. Eight weeks ago, she was prescribed an oral estrogen-progestin contraceptive for menorrhagia. The patient currently feels well and reports no fatigue, weight changes, constipation, or cold intolerance. Her vital signs are within normal limits. Physical examination reveals a normal, nonpalpable thyroid gland and no peripheral edema. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Measure serum thyroid-stimulating hormone concentration

Answer

Measure serum thyroid-stimulating hormone concentration
The most appropriate next step in management is to measure the serum thyroid-stimulating hormone (TSH) concentration. Oral estrogens undergo significant first-pass hepatic metabolism, which stimulates the liver to synthesize increased amounts of thyroxine-binding globulin (TBG). In a healthy individual, the resulting transient decrease in free T4 stimulates the pituitary gland to secrete more TSH, prompting the normal thyroid gland to produce more thyroid hormone and maintain a euthyroid state. However, patients with primary hypothyroidism lack this compensatory capacity. As a result, the increased TBG binds the exogenous levothyroxine, leading to a sustained decrease in free T4 and potentially causing clinical or subclinical hypothyroidism. Therefore, patients on levothyroxine who initiate oral estrogen therapy must have their TSH levels monitored 6 to 8 weeks after starting the medication to determine if an increase in the levothyroxine dosage is necessary. Even if the patient is currently asymptomatic, proactive testing is required as biochemical changes precede clinical symptoms.

Step-by-Step Solution

1
Identify the patient's underlying condition and recent medication changes.
The patient has primary hypothyroidism, is on a stable dose of levothyroxine, and recently started an oral estrogen-progestin contraceptive.
Establishing the temporal relationship between baseline therapies and newly added medications is necessary to identify potential drug interactions.
2
Analyze the pharmacokinetic effect of the new medication.
Oral estrogens undergo first-pass hepatic metabolism and stimulate the liver to synthesize increased amounts of thyroxine-binding globulin (TBG).
Understanding how oral estrogens alter serum transport proteins is required to predict changes in active hormone levels.
3
Determine the clinical consequence of this physiologic change.
Increased TBG binds more circulating T4, decreasing the biologically active free T4 fraction. Because the patient lacks endogenous thyroid function, she cannot compensate by producing more T4, placing her at risk for iatrogenic hypothyroidism.
This establishes the risk of clinical deterioration despite the patient currently being asymptomatic.
4
Select the appropriate monitoring strategy.
Measure the serum TSH level 6 to 8 weeks after the initiation of estrogen therapy to determine if a levothyroxine dose adjustment is required.
TSH is the most sensitive and accurate marker for assessing the adequacy of thyroid hormone replacement in primary hypothyroidism.

Key Concept

Monitoring levothyroxine therapy following the initiation of oral estrogens
Question 36Question →

A 33-year-old woman comes to the clinic to discuss her medication regimen. She was recently diagnosed with estrogen receptor-positive breast cancer and underwent a lumpectomy with sentinel lymph node biopsy two weeks ago. Her oncologist plans to initiate adjuvant tamoxifen therapy next week. The patient has a 5-year history of major depressive disorder, which has been well controlled for the past two years with daily paroxetine. She reports that her mood is currently stable and she has no neurovegetative symptoms of depression, though she is mildly anxious about starting her new cancer treatment. She has no other medical conditions and takes no other medications. Vital signs are within normal limits. Physical examination reveals a healing surgical incision on the right breast, with no erythema or discharge. Which of the following is the most appropriate next step in the pharmacologic management of this patient's depression?

Show answer & explanation

Answer: Discontinue paroxetine and initiate venlafaxine

Answer

Discontinue paroxetine and initiate venlafaxine
The correct course of action is to discontinue paroxetine and initiate venlafaxine. Tamoxifen is a selective estrogen receptor modulator (SERM) used as adjuvant therapy for hormone receptor-positive breast cancer. It is a prodrug that must be converted by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme into its highly active metabolite, endoxifen. Paroxetine is a strong inhibitor of CYP2D6. Co-administration of paroxetine and tamoxifen prevents the formation of endoxifen, leading to reduced therapeutic efficacy and an increased rate of breast cancer recurrence. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a weak or non-inhibitor of CYP2D6. It is considered a safe and highly effective alternative for treating depression (as well as hot flashes) in patients taking tamoxifen.

Step-by-Step Solution

1
Identify the patient's concurrent medications and planned therapies.
The patient is currently taking paroxetine for major depressive disorder and is scheduled to begin tamoxifen for estrogen receptor-positive breast cancer.
Medication reconciliation is the critical first step to avoid adverse drug events when new therapies are introduced.
2
Evaluate potential pharmacokinetic and pharmacodynamic interactions.
Paroxetine is identified as a strong CYP2D6 inhibitor. Tamoxifen is a prodrug that requires activation by CYP2D6 into its active metabolite, endoxifen.
Concomitant use of a strong CYP2D6 inhibitor prevents the activation of tamoxifen, significantly reducing its efficacy and increasing the risk of breast cancer recurrence.
3
Determine the appropriate clinical intervention to manage the interaction.
Select an effective alternative antidepressant that does not strongly inhibit CYP2D6, such as venlafaxine.
Venlafaxine safely maintains psychiatric stability without compromising the efficacy of the patient's critical oncologic therapy.

Key Concept

Management of drug-drug interactions involving CYP2D6 inhibitors and tamoxifen

Alternative Method

While venlafaxine is an excellent choice, selective serotonin reuptake inhibitors (SSRIs) that are weak or non-inhibitors of CYP2D6, such as escitalopram or citalopram, are also safe and viable alternative options for managing depression in patients on tamoxifen.
Estimated Time:1m 0s
Question 37Question →

A 26-year-old man comes to the clinic for treatment of a painless penile chancre. Darkfield microscopy confirms the presence of Treponema pallidum, and his baseline rapid plasma reagin (RPR) titer is 1:64. He is administered a single dose of intramuscular benzathine penicillin G for primary syphilis. He is otherwise healthy, has no allergies, and tests negative for HIV. The patient asks the physician how they will know if the infection has been successfully cured. Which of the following statements represent the appropriate monitoring and evaluation plan for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Repeat non-treponemal titer testing at 6 and 12 months after treatment.; Confirmation of at least a four-fold decrease in the non-treponemal titer.

Answer

The appropriate monitoring plan involves repeating the non-treponemal titer (RPR) at 6 and 12 months and confirming at least a four-fold decrease in the titer.
The correct answers identify that non-treponemal tests (such as RPR or VDRL) should be repeated at 6 and 12 months, and that a four-fold decrease in titer (e.g., from 1:64 to 1:16, representing two dilutions) is considered an adequate therapeutic response. Non-treponemal titers reflect current disease activity and decline gradually following successful treatment.

Step-by-Step Solution

1
Identify the patient's diagnosis and baseline laboratory status.
The patient has primary syphilis with a baseline RPR titer of 1:64.
Establishing the baseline titer is necessary because treatment success is evaluated relative to this initial quantitative value.
2
Select the appropriate laboratory test for longitudinal monitoring.
Non-treponemal tests (RPR or VDRL) are selected over treponemal tests (TP-PA, FTA-ABS).
Non-treponemal antibody levels correlate with active disease and decline after successful treatment, whereas treponemal antibodies typically remain positive for life.
3
Determine the correct monitoring intervals and criteria for cure.
Testing should be performed at 6 and 12 months to look for at least a four-fold decrease in the RPR titer (e.g., a drop from 1:64 to 1:16 or lower).
Antibody titers decline slowly. A four-fold drop by 6 to 12 months confirms adequate treatment response, even if the titer does not become entirely negative.

Key Concept

Monitoring and Treatment Evaluation for Primary Syphilis
Question 38Question →

A 31-year-old man is brought to the emergency department by his partner due to severe confusion, high fever, and intractable vomiting for the past 12 hours. The partner reports that the patient was diagnosed with Graves disease two years ago but has been nonadherent to all medications for the past three months. Temperature is 40.1°C (104.2°F), pulse is 155/min, blood pressure is 162/68 mm Hg, and respirations are 26/min. Physical examination reveals a profusely diaphoretic and delirious patient. A prominent fine tremor is noted in the upper extremities. Neck examination reveals a diffusely enlarged, non-tender thyroid gland with an audible bruit. Electrocardiography demonstrates sinus tachycardia.

Arrange the following pharmacologic interventions in the strictly required chronological sequence for the acute management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is intravenous propranolol, followed by oral propylthiouracil, followed by potassium iodide solution.
The management of thyroid storm requires a strict sequence of pharmacologic interventions to prevent exacerbating the condition. Intravenous propranolol is given first to rapidly control severe sympathetic symptoms (e.g., tachycardia, hyperpyrexia, agitation) and reduce peripheral conversion of T4 to T3. Next, a thionamide such as propylthiouracil (PTU) is administered to halt the synthesis of new thyroid hormone. Finally, an iodine solution (such as potassium iodide) is given to block the release of preformed thyroid hormone (the Wolff-Chaikoff effect). The iodine must be given at least one hour after the thionamide to ensure synthesis is completely blocked; otherwise, the iodine will serve as a substrate and worsen the hyperthyroidism.

Step-by-Step Solution

1
Administer intravenous propranolol
Rapid reduction in sympathetic overdrive and inhibition of peripheral T4 to T3 conversion
Immediate stabilization of cardiovascular status and control of adrenergic symptoms is the highest priority in thyroid storm.
2
Administer oral propylthiouracil (PTU)
Inhibition of thyroid peroxidase and blocking of new hormone synthesis
Synthesis of new thyroid hormone must be halted before exposing the hyperactive gland to a heavy iodine load.
3
Administer potassium iodide solution
Inhibition of preformed thyroid hormone release
Iodine must be given approximately 1 hour after PTU to prevent the iodine from being utilized as a substrate to produce more thyroid hormone.

Key Concept

Chronological pharmacologic sequence in the management of thyroid storm

Alternative Method

In patients with severe asthma or heart failure where non-selective beta-blockers like propranolol are contraindicated, alternative sympatholytic agents such as esmolol (cardioselective, short-acting) or diltiazem (calcium channel blocker) may be used as the first step.
Estimated Time:1m 0s
Question 39Question →

A 3838-year-old woman is evaluated in the clinic for progressive fatigue, weight gain, and cold intolerance over the past three months. Laboratory studies reveal a thyroid-stimulating hormone (TSH) level of 14.514.5 mIU/L (normal: 0.4−4.00.4-4.0 mIU/L) and a free thyroxine (T4) level of 0.60.6 ng/dL (normal: 0.9−1.70.9-1.7 ng/dL). She has no significant past medical history, takes no daily medications, and a urine pregnancy test is negative. She is diagnosed with primary hypothyroidism. Arrange the following steps in the correct chronological sequence regarding the initiation, monitoring, and evaluation of her thyroid hormone replacement therapy.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for monitoring and treatment evaluation in primary hypothyroidism begins with initiating weight-based levothyroxine, followed by checking TSH at 6 weeks, adjusting the dose as necessary, rechecking TSH 6 weeks after any adjustment, and finally transitioning to annual monitoring once a stable euthyroid state is achieved.
The management of primary hypothyroidism requires a stepwise approach to monitoring and treatment evaluation dictated by the pharmacokinetics of levothyroxine. The medication is initiated at a weight-based dose. Because it has a half-life of roughly 7 days, checking TSH before 4 to 6 weeks will yield an inaccurate assessment of the dose's efficacy. Therefore, the first TSH check is appropriately delayed to 6 weeks. If the TSH is not at goal, the dose is adjusted, which necessitates another 6-week waiting period to evaluate the new steady state. Once a patient is clinically and biochemically euthyroid on a stable dose, monitoring can safely be extended to annual intervals.

Step-by-Step Solution

1
Initiate oral levothyroxine at a full replacement dose of approximately 1.6 mcg/kg daily.
The patient begins thyroid hormone replacement.
This is the standard starting step and dose for young, healthy adults without coronary artery disease.
2
Measure serum TSH levels 6 weeks after initiating therapy.
The initial steady-state TSH level is evaluated.
Levothyroxine has a 7-day half-life, so it takes 4-6 weeks to reach steady-state serum concentrations and accurately reflect pituitary suppression.
3
Adjust the levothyroxine dose by 12.5 to 25 mcg daily based on the initial follow-up TSH level.
The daily dose is optimized to target the normal TSH range.
If the initial TSH is not at goal, small incremental adjustments are necessary to prevent over- or under-replacement.
4
Repeat serum TSH measurement 6 weeks after the dose adjustment.
The effect of the new dose on the pituitary-thyroid axis is evaluated.
Just like the initial initiation, any dose adjustment requires another 4-6 week waiting period to reach a new steady state.
5
Transition to annual TSH monitoring once a stable, euthyroid maintenance dose is confirmed.
Long-term surveillance is established.
Once euthyroidism is achieved on a stable dose, the patient requires yearly checks to ensure the dose remains appropriate.

Key Concept

Chronological timeline for monitoring and evaluating levothyroxine replacement therapy based on medication pharmacokinetics.
Question 40Question →

A 7474-year-old man is evaluated on the inpatient medical ward. He was admitted 33 days ago for a severe exacerbation of chronic obstructive pulmonary disease. His home medications include warfarin for permanent atrial fibrillation and a tiotropium inhaler. On admission, he was started on intravenous methylprednisolone and oral levofloxacin. Today, he reports feeling much better with decreased dyspnea and minimal cough. His vital signs are stable, with a blood pressure of 128/76128/76 mm Hg and a heart rate of 7878/min. Routine morning laboratory results show an International Normalized Ratio (INR) of 7.27.2 (target 2.02.0-3.03.0). Physical examination reveals no petechiae, ecchymoses, or signs of gastrointestinal bleeding. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Show answer & explanation

Answer: Omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.

Answer

The most appropriate next step is to omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.
The correct answer involves withholding the next one to two doses of warfarin and monitoring the patient's coagulation profile. Current clinical guidelines state that for patients taking warfarin who present with an asymptomatic supratherapeutic INR between 4.54.5 and 1010, the routine use of phytonadione (Vitamin K) is not recommended. The safest and most effective approach is to hold warfarin until the INR falls back into the therapeutic range (2.02.0-3.03.0), and then resume it at a lower dose if the interacting medications (in this case, levofloxacin and methylprednisolone) are continued.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and laboratory results.
The patient has an asymptomatic supratherapeutic INR of 7.2 without any signs of active bleeding.
Determining the presence or absence of active bleeding is the critical branching point in managing warfarin-associated coagulopathy.
2
Identify the likely cause of the coagulopathy.
The recent addition of levofloxacin and methylprednisolone caused a pharmacokinetic interaction, inhibiting warfarin metabolism and altering gut flora.
Understanding the etiology helps guide future dose adjustments once the INR returns to the therapeutic range.
3
Apply evidence-based guidelines for supratherapeutic INR reversal.
For an INR between 4.5 and 10 without bleeding, guidelines recommend holding 1-2 doses of warfarin rather than administering pharmacological reversal agents.
Routine use of Vitamin K in this range provides no outcome benefit and can cause warfarin resistance, while PCC is exclusively for life-threatening hemorrhage.

Key Concept

Management of supratherapeutic INR without bleeding
PreviousPage 2 / 104Next
Patient Management Practice Questions — USMLE Step 3 — Page 2 | Examkin